Articles tagged with Antidiabetics
Researchers have found a potential side effect of GLP-1 receptor agonists used to treat type 2 diabetes: an increased risk of non-scarring alopecia. The absolute risk is low, but awareness may inform treatment decisions. Rapid weight loss and hormonal changes are thought to be contributing factors.
A new study in the Canadian Journal of Cardiology predicts that generic semaglutide will dramatically increase cost-effectiveness and health system affordability for patients with type 2 diabetes and high cardiorenal risk. The estimated annual cost of providing GLP-1RAs to all indicated patients would be $3.35 to $5.31 billion at pre-g...
The summit brought together endocrine leaders to identify opportunities to work closely together on increasing the visibility of endocrine health in policy decisions. Early findings from a workforce survey revealed challenges including long patient waiting times and retention concerns among early-career clinicians.
Researchers identified patient-reported symptoms associated with GLP-1s, including menstrual changes, fatigue, and temperature-related complaints, that may not be fully captured in clinical trials or drug labeling. Nearly 4% of Reddit users reported reproductive symptoms, and fatigue was the second most common complaint.
Researchers have developed a low-cost fake drug detector that uses an infrared sensor to track pill dissolution rates. The device can identify legitimate medications from counterfeit ones with high accuracy, making it a valuable tool in the fight against global health threats.
A new study by Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System found that using GLP-1 receptor agonists in combination with adhering to healthy lifestyle habits significantly reduces cardiovascular risk among individuals with type 2 diabetes. The study showed that these two stra...
A new study finds salcaprozate sodium may have adverse biological effects on the gut and beyond, including shifts in potentially harmful gut bacteria and elevated inflammatory markers. The research highlights an important gap in understanding the long-term impact of repeated SNAC exposure.
Researchers analyzed insurance claims data from US health insurers to demonstrate the cardiovascular benefits of semaglutide and tirzepatide. Both GLP-1 drugs provide cardioprotective effects, reducing the risk of stroke and heart attack by 18% and 13%, respectively.
Researchers revealed the molecular mechanism of acarbose degradation by acarbose-preferred glucosidase, identifying key nucleophiles and substrates. The two-step degradation mechanism involves an M1 intermediate, providing targets for designing novel anti-degradation diabetes therapeutics.
Research highlights preventable harms of intensive diabetes and hypertension treatment in frail older adults, calling for personalized care approaches that prioritize patient safety. Guidelines recommend cautious individualized care, but complications remain alarmingly common.
A new study found that the newer generation of effective diabetes medications are not reaching enough patients. The study analyzed data from over 40,000 records and found that only 20% of patients with type 2 diabetes were taking GLP-1 drugs within a year of diagnosis, and less than 15% were taking SGLT2 drugs.
A new study reveals that Rapamycin has a comparable life-extending effect to dietary restriction in eight species of vertebrates. The compound, originally developed as an immunosuppressant, offers similar benefits without the need for caloric restriction.
A study by University of Gothenburg researchers found that consuming sulforaphane from broccoli sprouts improved blood sugar levels in people with prediabetes. The compound had a significant effect on fasting blood sugar levels, particularly in those with certain pathophysiological and microbiome characteristics.
The novel compound HPH-15 outperforms metformin by activating AMPK at lower doses, improving glucose uptake and reducing fat accumulation in high-fat diet-induced obese mice. Additionally, it exhibits antifibrotic properties, potentially addressing liver fibrosis.
Researchers found that GLP-1 receptor agonists reduced the risk of kidney failure by 16% and worsening of kidney function by 22%. The combined reduction in risk was 19%, showing a clear benefit on kidney protection. This study expands current knowledge about this class of drugs, highlighting their role in treating patients with chronic...
New research compares four methods for extracting edible insect protein, finding that alkali extraction boosts protein content while enzyme treatment improves nutritional value. Additionally, salt-assisted extraction reveals anti-inflammatory effects and anti-diabetic properties.
A new University of Michigan study found that over 82% of Americans aged 50-80 take one or more prescription medications, with 80% open to stopping certain drugs. However, researchers stress the importance of personalized guidance for deprescribing older adults, particularly those taking medication for cardiovascular disease or diabetes.
Researchers analyzed over 1.5 million patient records to find that metformin and SGLT-2 inhibitors lowered dementia and Alzheimer's disease risks compared to other antidiabetic drugs. The study suggests individualized treatment approaches considering patient-specific factors for optimal diabetes management.
Researchers found that metformin increases levels of microRNAs miR-2110 and miR-132-3p, targeting genes PIK3R3 and STMN1 to slow down cancer cell growth and division. This study provides new insights into metformin's molecular mechanisms and its potential as a preventive agent for reducing cancer growth.
US pharmaceutical spending surged to $473.12 billion from 2011 to 2020, with diabetic medications accounting for a significant increase. The study found that antidiabetic agents were the most expensive therapeutic area, with Medicare and Medicaid contributing significantly to the costs.
A University of Cincinnati study found liraglutide to be efficacious and safe for weight loss in individuals with stable bipolar disorder, without destabilizing the illness. The drug reduced binge eating behavior and significantly lowered hemoglobin A1C levels.
A new study found no increased risk of major congenital malformations in infants exposed to second-line non-insulin antidiabetic medications during pregnancy compared to those treated with insulin. The study examined over 3.5 million pregnancies and provided reassurance on the safety of these medications for fetuses.
This article discusses the antidiabetic properties of two important spices, Trachyspermum ammi and Pimpinella anisum. The spices, native to the Umbelliferae family, have been traditionally used as carminatives, aromatics, disinfectants, and galactogogues.
A recent study found that metformin users had distinct DNA methylation profiles compared to non-users, potentially revealing its role in longevity. The research identified several pathways related to delirium and aging, highlighting the need for further investigation into metformin's mechanism of action.
Acylated anthocyanins found in purple potatoes, sweet potatoes, and carrots have been shown to reduce type 2 diabetes risk by affecting glucose transporters and enzymes involved in metabolism. These compounds also maintain gut microbiota homeostasis and suppress pro-inflammatory pathways.
Research reveals that opioid tapering can lead to more hospitalizations and emergency department visits, while also reducing primary care visit rates. The study's findings suggest potential unintended consequences of opioid tapering for policymakers and clinicians.
Researchers found that xanthan gum-based fluid thickener decreases postprandial blood glucose levels by increasing Glp1 and Glp1r expression in the ileum. Additionally, the study reveals alterations in gut microbiome composition, favoring beneficial bacteria that produce short-chain fatty acids to protect intestinal cells.
Researchers at Karolinska Institutet have identified a new antidiabetic substance that preserves beta cell activity and prevents high blood glucose in mice. This approach may prevent the exhaustion of beta cells and improve long-term diabetes treatment.
The article suggests a potential treatment option for COVID-19 by targeting SARS-CoV-2's interaction with ACE2 receptors. Combining DPP4 inhibitors and spironolactone may mitigate COVID-19 complications and infections without adverse side effects.
A retrospective study published in Mayo Clinic Proceedings found that dasatinib lowers serum glucose levels in patients with pre-existing type 2 diabetes to a greater degree than imatinib and comparable to first-line diabetic medications. Researchers suggest further study is needed to determine the primary mechanism behind dasatinib's ...
A new anti-diabetic compound, Montbretin A (MbA), has been approved by Health Canada for Phase 1 human trials. MbA works by inhibiting the alpha-amylase enzyme, slowing down starch breakdown and reducing blood sugar spikes in Type 2 diabetics.
Researchers found that certain species of gut bacteria accumulate human drugs, altering their types, activity, and metabolism. This can change the effectiveness of the drug both directly and indirectly, affecting side effects.
A University at Buffalo-led study found that SGLT2 inhibitors cause a median weight loss of over 6 pounds in Type 2 diabetes patients, compared to 2.5 pounds with GLP-1 receptor agonists. The findings suggest that SGLT2 inhibitors may be more protective against weight gain caused by other antidiabetic drugs.
Researchers at Kumamoto University discovered that metformin prolongs survival of mice with non-diabetic chronic kidney disease by reducing kidney function and inflammation. The study suggests that a combination of metformin and losartan may be beneficial for patients with ND-CKD.
A study analyzing 4,000 social media posts found that diabetics in the UK fear disrupted insulin supplies as a result of Brexit. The research highlights the financial burden of accessing insulin and the need for improved healthcare systems.
A systematic review and network meta-analysis suggest metformin-based therapy as a preferred first-line treatment for drug-naive patients with type 2 diabetes at low cardiovascular risk. Insulin regimens and GLP-1 RAs added to metformin-based background therapy produced the greatest reductions in hemoglobin A1c level.
A computational study identified lansoprazole and 12 other FDA-approved drugs that reduce inflammation and may prevent preterm birth. The drugs act on biological pathways affecting the immune response, which is implicated in preterm birth. Further testing is needed to confirm their effectiveness.
Research found patients with highly variable blood sugar control are more likely to experience adverse cardiovascular events and microvascular complications. The study suggests that even a moderate increase in HbA1c variability is associated with increased risks of mortality, cardiovascular disease, and diabetes-related complications.
Researchers found that metformin reduces anxiety-like behaviors in male mice by increasing serotonin availability in the brain. This increase was accompanied by improved neurotransmission in the hippocampus and lower levels of amino acids that impair serotonin production.
Researchers at Wake Forest School of Medicine discovered that gut bacteria can enhance or inhibit the effectiveness of anti-diabetes drugs. The review of over 100 studies suggests that modulation of the gut microbiome may be a target to improve or reverse medication efficacy for type-2 diabetes.
Researchers found that people with Alzheimer's disease who were treated with diabetes drugs showed fewer markers of the disease, including abnormal microvasculature and gene expressions. The study suggests targeting the brain's capillary system could have beneficial effects in Alzheimer's patients, opening opportunities for new therapies.
A research consortium investigated the antidiabetic action of natural fatty acids, but found no positive effects on metabolism. Previous studies had suggested a potential point of attack in treating diabetes, but these results do not support it.
A recent study published in The BMJ found that dipeptidyl peptidase-4 inhibitors, a type of diabetes drug, are associated with an increased risk of inflammatory bowel disease. The study analyzed data from over 141,000 patients and found a 75% higher incidence rate compared to other antidiabetic drugs.
A University of Guelph study found that intense exercise before taking a daily dose of olanzapine can reduce the risk of weight gain and Type 2 diabetes. The researchers discovered that moderate exercise did not have the same effect, highlighting the importance of intense physical activity in mitigating medication side effects.
A common rheumatoid arthritis treatment, lefluonamide, lowered blood glucose levels and reversed insulin resistance in mouse models of type 2 diabetes. The study suggests that this therapy could be repurposed as an effective antidiabetic treatment for patients with both diabetes and rheumatoid arthritis.
A recent analysis revealed that proprietary Chinese medicines (pCMs) are frequently adulterated with undeclared agents, posing serious health hazards. The study identified 404 cases involving 487 adulterated pCMs or health products, with 65% of patients experiencing adverse effects.
TSRI researchers studied the interactions between Avandia, a nuclear receptor, and coregulatory protein SRC-2, revealing how DNA binding affects drug potency and receptor shape. This knowledge could lead to designing new antidiabetic drugs with better efficacy and fewer side effects.
A study by NIH-funded researchers found that policies restricting pharmaceutical promotion to physicians resulted in fewer prescribed promoted drugs and more non-promoted drugs in the same drug classes. The analysis encompassed over 16 million prescriptions, showing a modest but significant decline in the use of promoted drugs.
Research found that patients diagnosed with type 2 diabetes are at increased risk of developing pancreatic cancer, particularly within the first year. The study's findings suggest a link between rapid deterioration in diabetes and early detection of pancreatic cancer.
Researchers have identified flavonoids in Gymnema sylvestre R.Br. plant parts and callus culture, which exhibit antidiabetic properties. The study aimed to develop a sustainable method for metabolite production using tissue culture, helping conserve the endangered species.
Researchers studied 880 MCI patients and found that the majority took at least one medication, with 40% taking four or more. The study highlights the importance of caution when prescribing medications to elderly patients, particularly those with anticholinergic effects.
Researchers have identified a new biochemical pathway that can be controlled using metformin and salicylate, two widely used medicines. This approach could lead to the development of new therapies for inflammatory disorders, including those caused by faulty Janus kinase proteins.
A genetic approach has been demonstrated to identify potential side effects of new diabetes drugs at early stages of development. Researchers used genetic data from over 12,000 individuals and found a variant in the GLP1R gene associated with lower fasting glucose and reduced risk of type 2 diabetes.
A new study discovered a genetic variant that reduces the risk of coronary heart disease in people taking antidiabetic medications, contradicting previous assumptions about these drugs' safety. The variant was linked to the glucagon-like peptide-1 receptor and may provide valuable insights for predicting drug side effects earlier in th...
Researchers have created a light-activated tool to adapt drugs for type 2 diabetes. The study provides insight into cellular receptor signalling and could lead to more efficient anti-diabetic drugs. The new tool, PhotoETP, allows precise control over blood glucose levels with fewer side effects.
A large-scale study examining the relationship between incretin-based drugs and hospitalization for heart failure found no increased risk. The study, conducted by the Canadian Network for Observational Drug Effect Studies (CNODES), analyzed health records of over 1.4 million patients in Canada, the US, and the UK.
A new study published in the Lancet found that metabolic or bariatric surgery was more effective than standard medical treatment for the long-term control of type 2 diabetes in obese patients. Surgery resulted in better glycemic control, lower levels of blood glucose, and reduced need for anti-diabetic medication.
A Penn study found that natural genetic differences in DNA sequence can determine how an anti-diabetic drug works, shedding light on personalized approaches to treating diabetes and related disorders. The research suggests that genetic variations can affect drug response, which could lead to more effective treatments.
Researchers at Scripps Research Institute are accelerating development of anti-diabetic compounds, focusing on peroxisome proliferator-activated receptors gamma (PPARG) and overcoming glitazone safety concerns. The new grant aims to inform clinical development and assess effects on bone.
A study analyzing health insurance data found that long-term treatment with pioglitazone significantly decreases the risk of developing dementia in patients with type 2 diabetes. The medication lowers the risk by approximately half compared to non-diabetics, with a notable protective effect against Alzheimer's disease.